A Randomized Phase IIB Open Label Study of Nivolumab in combination with Ipilimumab versus Bevacizumab in Adult Subjects with Recurrent Glioblastoma (GBM)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
The Bristol-Myers/Sanofi Pharmaceuticals, Inc. Partnership
Start Date
February 1, 2014
End Date
January 31, 2021
Administered By
Duke Cancer Institute
Awarded By
The Bristol-Myers/Sanofi Pharmaceuticals, Inc. Partnership
Start Date
February 1, 2014
End Date
January 31, 2021